Medical Action Myanmar
Yangon, Burma
NCT Number: NCT02020330
This is a randomised two arm study, comparing artemether-lumefantrine 3 days and 5 days treatment. Patients will be randomised in blocks of ten to one of the two treatment arms. The standard regimen is twice daily for three days with a delay of at least eight hours between the first and second doses. A single of primaquine will be given to all patients on the first day of treatment for gametocytocidal activity. The initial treatment will be given under supervision, all other subsequent doses will be given to the patient to the taken at home. Patients will be followed up for nine visits over forty two days.
Looking for future studies?
Notify Me6 year and older
All sexes
Interventional
Phase 3
Yangon, Burma
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
One tablet contains 20mg artemether and 120mg lumefantrine. The standard regimen is twice daily for 3 days with a delay of at least 8 hours between the first and second dose. It is dosed by weight categories. One gram of fish oil will be given to half of the participants in the 3 days arm.
Other names: Coartem®, Novatis, Switzerland
One tablet contains 20mg artemether and 120mg lumefantrine. The experiment regimen is twice daily for 5 days with a delay of at least 8 hours between the first and second dose. It is dosed by weight categories. One gram of fish oil will be given to half of the participants in the 5 days arm.
Other names: Coartem®, Novartis, Switzerland
Time frame: On day 5 and day 7
Assessed by sensitive PCR on days 5 and 7 after treatment
Time frame: On day 3 and Day 5
Assessed by sensitive PCR on D3 in the 3 day arm and D5 in the 5 day arm
Time frame: Day 7
Time frame: 5 days
Tolerability of artemether-lumefantrine will be assessed by comparing the proportion of patients with anorexia, nausea, vomiting, abdominal pain and other symptoms of administration between the intervention arm and the control arm
Time frame: Day 42
Comparison of effectiveness uncorrected and corrected will be assessed by PCR genotyping
Time frame: Day 7
Time frame: Day 28
Assessed by comparing hemoglobin between baseline and after treatment at day 28
Time frame: 42 days
Assessed by the microscopist find malaria smear positive within the follow up period
Time frame: day 3 to day 21
Assessed by comparing lumefantrine concentration on day 7 and proportion of patients with detectable parasitaemia by qPCR
University of Oxford
Other
An Open-label Randomized Controlled Trial to Evaluate the Effectiveness and Safety of a 3 Day Versus 5 Day Course of Artemether-lumefantrine for the Treatment of Uncomplicated Falciparum Malaria in Myanmar
Acronym: AL3vs5
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07122232
Blood Platelet Disorders, Cytopenia
Peshawar, KPK, Pakistan
View Trial DetailsNCT05816330
Infections, Malaria
Faladiè, Koulikoro, Mali
View Trial DetailsNCT03168854
Infections, Malaria
Seattle, Washington, United States
View Trial DetailsNCT02780154
Infections, Malaria
Baltimore, Maryland, United States
View Trial Details